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Abstract
Background and Purpose: Voltage-gated calcium channels are involved in nociception in the CNS and in the
periphery. N-type (Cav2.2) and T-type (Cav3.1, Cav3.2 and Cav3.3) voltage-gated calcium channels are
particularly important in studying and treating pain and epilepsy. Experimental Approach: In this study,
whole-cell patch clamp electrophysiology was used to assess the potency and mechanism of action of a novel
ortho-phenoxylanilide derivative, MONIRO-1, against a panel of voltage-gated calcium channels including
Cav1.2, Cav1.3, Cav2.1, Cav2.2, Cav2.3, Cav3.1, Cav3.2 and Cav3.3. Key Results: MONIRO-1 was 5- to
20-fold more potent at inhibiting human T-type calcium channels, hCav3.1, hCav3.2 and hCav3.3 (IC50 : 3.3
± 0.3, 1.7 ± 0.1 and 7.2 ± 0.3 μM, respectively) than N-type calcium channel, hCav2.2 (IC50 : 34.0 ± 3.6 μM).
It interacted with L-type calcium channels Cav1.2 and Cav1.3 with significantly lower potency (IC50 > 100
μM) and did not inhibit hCav2.1 or hCav2.3 channels at concentrations as high as 100 μM. State- and use-
dependent inhibition of hCav2.2 channels was observed, whereas stronger inhibition occurred at high
stimulation frequencies for hCav3.1 channels suggesting a different mode of action between these two
channels. Conclusions and Implications: Selectivity, potency, reversibility and multi-modal effects
distinguish MONIRO-1 from other low MW inhibitors acting on Ca v channels involved in pain and/or
epilepsy pathways. High-frequency firing increased the affinity for MONIRO-1 for both hCav2.2 and hCav3.1
channels. Such Cav channel modulators have potential clinical use in the treatment of epilepsies, neuropathic
pain and other nociceptive pathophysiologies.
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BACKGROUND AND PURPOSE 
Voltage-gated calcium channels are involved in peripheral and central nervous system 
nociception. N-type (Cav2.2) and T-type (Cav3.1, Cav 3.2 and Cav 3.3) voltage-gated calcium 
channels are particularly important in studying and treating pain and epilepsy. 
 
EXPERIMENTAL APPROACH 
In this study, whole-cell patch clamp electrophysiology was used to assess the potency and 
mechanism of action of a novel ortho-phenoxylanilide derivative, MONIRO-1, against a 
panel of voltage-gated calcium channels including Cav1.2, Cav1.3, Cav2.1, Cav2.2, Cav2.3, 
Cav3.1, Cav3.2 and Cav3.3.  
 
KEY RESULTS 
MONIRO-1 was 5-20-fold more potent at inhibiting human T-type calcium channels, 
hCav3.1, hCav3.2 and hCav3.3 (IC50: 3.3 ± 0.3 µM, 1.7 ± 0.1 µM and 7.2 ± 0.3 µM, 
respectively) than N-type calcium channel, hCav2.2 (IC50: 34.0 ± 3.6 µM). It interacts with L-
type calcium channels Cav1.2 and Cav1.3 with significantly lower potency (IC50 >100 µM), 
and does not inhibit hCav2.1 or hCav2.3 at concentrations as high as 100 µM. Interestingly, 
state- and use-dependent inhibition of hCav2.2 was observed, whereas stronger inhibition 
occurred at high stimulation frequencies for hCav3.1 suggesting a different mode of action 
between these two channels.  
 
CONCLUSIONS AND IMPLICATIONS 
Selectivity, potency, reversibility and multi-modal effects distinguish MONIRO-1 from other 
small molecule inhibitors acting on Cav channels involved in pain and/or epilepsy pathways. 
For both hCav2.2 and hCav3.1, high frequency firing increases the affinity for MONIRO-1 for 
both channels.  Such Cav channel modulators have potential clinical use in the treatment of 
epilepsies, neuropathic pain and other nociceptive patho-physiologies. 
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INTRODUCTION 
 
 Sensory nerve conduction relies on the coordinated activation of a suite of ion 
channels to generate fast and accurate responses to mechanical, thermal and chemical 
stimuli. In the periphery, harmful signals are perceived by ‘nociceptive’ neurons and 
relayed centrally via voltage-activated ion channels (Kv, Nav, Cav) and ligand-gated 
ion channels (TRP, K2P, P2X) (Waxman et al., 2014) as part of the ‘pain-signalling 
cascade’ (Gold et al., 2010). In chronic pain, these pathways are characterized by 
hyperactivity (Waxman et al., 2014) and the effects of noxious stimuli are enhanced 
(hyperalgesia) to the point where non-noxious stimuli are painful (allodynia) (see 
recent review by Guo and Hu (Guo et al., 2014)). Voltage-gated calcium channels 
(VGCCs) involved in pain pathways are localized to dendrites of primary sensory 
neurons and contribute to integrate nociceptive stimuli at the spine by regulating the 
release of pro-nociceptive neurotransmitters, including substance P, calcitonin gene-
related peptide and glutamate, at the presynaptic nerve terminus (Simms et al., 2014). 
Therefore, modulating specific Cav subtypes could be a promising way to treat chronic 
pain. 
 Five distinct voltage-gated calcium current types have been described in 
mammalian cells: L- (Cav1.1-1.4), P/Q- (Cav2.1), N- (Cav2.2), R- (Cav2.3) and T- 
(Cav3.1-3.3) types (Catterall et al., 2005). Importantly, each Cav subtype has distinct 
electrophysiological properties, tissue-specific localization and pharmacological 
profiles (Catterall et al., 2005). N-type calcium channels have been a major focus of 
research because they are localized at the presynaptic terminals of sensory nerves in 
the dorsal horn of the spinal cord, where they play a critical role in pain signalling 
(Lee, 2014; Saegusa et al., 2001). As a result, Cav2.2 channels are strongly implicated 
in a range of chronic pain conditions including neuropathic pain (pain caused by injury 
to the nervous system). Specific Cav2.2 channel inhibitors have clinical applications 
(Altier et al., 2004; Bourinet et al., 2014; Perret et al., 2009), such as ω-conotoxin 
MVIIA (Ziconotide). Ziconotide selectively targets Cav2.2 channels and is used to 
effectively treat intractable chronic pain conditions (Pope et al., 2013). However, due 
to its chemical nature, Ziconotide must be administered into the cerebrospinal fluid via 
the intrathecal route and has a relatively narrow therapeutic window (Pope et al., 
2013).
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T-type calcium channels modulate neuronal excitability in the peripheral and 
central nervous systems, where they are linked to hyperexcitable states such as 
epilepsy, pain and tremor disorders like Parkinson’s disease (Bourinet et al., 2005; 
Choi et al., 2007; Kim et al., 2001). Previously characterized T-type calcium channels 
inhibitors, such as mibefradil and ethoximide, have analgesic properties, suggesting 
that T-type channels may be involved in pain signalling (Flatters et al., 2004; 
Matthews et al., 2001; Todorovic et al., 2002; Wen et al., 2010). Unfortunately, 
mibefradil and ethoximide target a wide range of voltage-gated ion channels, including 
sodium, potassium and chloride channels (Chouabe et al., 1998; Eller et al., 2000; 
Nilius et al., 1998).  
 To overcome this lack of specificity, small molecule T-type calcium channel 
inhibitors were designed and have been shown to provide analgesic effects in mouse 
models of inflammatory and neuropathic pain (Bladen et al., 2015; Kraus et al., 2010; 
Reger et al., 2011). Of particular note is the analgesic, small molecule TTA-A2, which 
is more potent against inactivated than closed or resting channels (IC50 values of 100 
nM and 10 µM at Cav3.1, respectively), indicating its effects on targets are state-
dependent (Francois et al., 2013). Based on these findings, N- and T-type calcium 
channels are of particular interest for the study and treatment of pain (see recent 
reviews by (Cheong et al., 2013; François et al., 2014; Lee, 2014; Lee, 2013; 
Sekiguchi et al., 2013; Simms et al., 2014).
 
 During the last five years, numerous reports have described small molecule Cav2.2 
channel inhibitors as alternatives to Ziconotide (see review by Lee (Lee, 2014)). 
Regrettably, clinical development of the most promising of these small-molecules, 
Z160, a reformulated form of NP118809 (Zamponi et al., 2009) (compound 1, Fig. 1), 
was discontinued after it failed to meet end points in phase II clinical trials (Eller et al., 
2000). Due to this and the need for effective and safe therapeutics for chronic pain, the 
development of new classes of small-molecule Cav channel antagonists is of 
significant interest.  
 The pharmacophore of Cav2.2-selective ω-conotoxin GVIA (Andersson et al., 
2009; Baell et al., 2004; Baell et al., 2006; Duggan et al., 2009; McCleskey et al., 
1987) has been carefully studied and has led to the identification of a series of 
compounds that block Cav2.2 channels in a concentration-dependent manner 
(Tranberg et al., 2012).  
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 We focused on developing low molecular weight calcium channel inhibitors with 
enhanced biophysical properties including reversibility, voltage- and/or state-
dependence. Compounds acting via these mechanisms can strongly inhibit channels 
upon membrane depolarization (Butterworth et al., 1990; Hondeghem et al., 1984) by 
preferentially targeting the open and/or inactivated states over the resting state. Such 
compounds would facilitate inhibition of high-frequency firing or depolarised nerves 
that can predominate in chronic pain states, and could act within a wider therapeutic 
window.  
 To develop these calcium channel inhibitors, we screened a small library of related 
derivatives, using FLIPR Tetra
®
 high-throughput cellular screening system, for their 
ability to inhibit Cav2.2-mediated calcium responses in SH-SY5Y cells using the 
fluorescent indicator Calcium 4 dye (Molecular Devices, Sunnycale, CA, USA) 
(Gleeson et al., 2015). In this assay, MONIRO-1 inhibited Ca
2+
 responses elicited by 
KCl-mediated depolarization with an IC50 of 124 µM. Subsequently, we characterized 
the ortho-phenoxyanilide derivative MONIRO-1 (Compound 2, Fig. 1) 
electrophysiologically.  To directly assess the biophysical properties of MONIRO-1 
inhibition of voltage-gated calcium channels, we used the whole-cell patch clamp 
recording technique to study a comprehensive array of Cav channels heterologously or 
stably expressed in HEK-293 cells. MONIRO-1 was 5−100 times more potent against 
T-type calcium channels (Cav3.1, Cav3.2 and Cav3.3) than N-type (Cav2.2) and L-type 
(Cav1.2 and Cav1.3) channels. No inhibition of P/Q (Cav2.1) or R-type currents 
(Cav2.3) was detected in the presence of up to 100 µM MONIRO-1. Furthermore, 
MONIRO-1 modulated Cav2.2 differently at various stimulation rates and in a state-
dependent fashion, preferentially inhibiting hyperactive channels such as those likely 
to predominate in pathologically augmented pain states.  
 
1. METHODS 
1.1 Chemical synthesis.  
 Compound 2, N-(2-(4-fluorophenoxy)phenyl)-4-(3-guanidinopropoxy)benzamide 
hydrochloride, MONIRO-1, was synthesized from 2-(4-fluorophenoxy)aniline in four 
steps, as reported previously (Gleeson et al., 2015). 
1
H NMR (400 MHz, CD3OD): δ 
7.88-7.85 (m, 1H), 7.78-7.76 (m, 2H), 7.21-7.18 (m, 2H), 7.07-6.98 (m, 6H), 6.97-6.94 
(m, 1H), 4.13 (t, J = 5.9 Hz, 2H), 3.41 (t, J = 6.8 Hz, 2H), 2.11-2.05 (m, 2H). 
13
C 
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NMR (100 MHz, CD3OD): δ 168.2, 163.2, 160.2 (d, J = 239 Hz), 158.7, 154.4, 151.0, 
130.5, 130.4, 127.9, 127.6, 126.9, 125.0, 120.8 (d, J = 8.3 Hz), 120.1, 117.2 (d, J = 
23.4 Hz), 115.4, 66.3, 39.5, 29.5. 
19
F NMR (376 MHz, CD3OD): δ -120.6, purity > 
92%, determined by HPLC analysis (λ = 254 nm), all tests were performed using the 
same batch of compound. The positive control, compound 1 (Z160/NP118809) 
(Zamponi et al., 2009; Zikolova et al., 1972), was prepared by N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide-assisted acylation of N-benzhydryl 
piperazine with 3,3-diphenylpropanoic acid.  Control compound NNC 55-0396 
dihydrochloride was provided by Alomone Labs (Jerusalem, Israel). 
 
1.2 Cell culture and transfection.  
 HEK293 cells containing the SV40 Large T-antigen (HEK293T) were cultured at 
37 °C, 5% CO2 in Dulbecco’s Modified Eagle’s Medium (Invitrogen Life 
Technologies, Australia) supplemented with 10% fetal bovine serum (Invitrogen), 1% 
penicillin and streptomycin (Invitrogen). HEK293T cells stably expressing the human 
Cav2.1 (P/Q-type) calcium channel (α1A-2 splice variant; GenBank accession no. 
AF004883.1), Cav2.2 (N-type) calcium channel (transcript variant 1, NM_000718) or 
Cav2.3 (R-type) calcium channel (neuronal α1E-3 splice variant, also called α1E-c, 
L29385.1) were obtained from Merck and cultured according to procedures described 
by Dai et al. (Dai et al., 2008). These cell lines co-express recombinant human Cav 
α2bδ-1 (M76559.1) and Cav β3a (NM_000725) auxiliary subunits (Dai et al., 2008). 
Cells are plated onto 12 mm cover glass and incubated at 30 °C, 5% CO2 for 24-48 
hours prior to recording. 
 In a separate series of experiments, HEK293T cells were transiently co-transfected 
with plasmid cDNAs encoding human Cav1.3 (provided by Dr G. Zamponi, University 
of Calgary) with α2δ-1 and β3, Cav3.1 (provided by Dr G. Zamponi), human Cav3.2 
(CACNA1HB; Origene Technologies, Rockville, MD), human Cav3.3 a1Ic-HE3-
pcDNA3 was a gift from Edward Perez-Reyes(Gomora et al., 2002) (Addgene plasmid 
# 45810) and Kv11.1 (hERG) (provided by Dr J. Vandenberg, Victor Chang Cardiac 
Research Institute, Sydney). After transfection, cells were plated on glass coverslips 
and incubated at 37 °C, 5% CO2 overnight. The transfection medium was then 
replaced with culture medium and cells were incubated at 30 °C, 5% CO2. 
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1.3 Electrophysiology. 
 Electrophysiological experiments were carried out 1-3 days after transfection 
using the whole-cell patch clamp recording technique. Cells were superfused with a 
solution containing 110 mM NaCl, 10 mM CaCl2, 1 mM MgCl2, 5 mM CsCl, 30 mM 
TEA-Cl, 10 mM d-glucose and 10 mM HEPES, pH 7.4 with TEA-OH (~310 
mOsmol/kg). Fire-polished borosilicate patch pipettes with tip-resistance values of 1–3 
MΩ were filled with an intracellular solution containing 125 mM Kgluconate, 5 mM 
NaCl, 2 mM MgCl2, 5 mM EGTA, 4 mM MgATP and 10 mM HEPES, pH 7.2 with 
CsOH (~300 mOsmol/kg). Depolarization-activated calcium currents were recorded at 
room temperature (21-23 °C) using a Multiclamp 700B patch clamp amplifier 
(Molecular Devices, Sunnyvale, CA) controlled by DigiData 1322/Clampex 9.2 
acquisition systems. MONIRO-1 stock solution was dissolved in 5% DMSO to a 
concentration of 5 mM.  MONIRO-1 was further diluted in recording solution to 
appropriate concentrations.  Previous experiments using the maximal concentration of 
DMSO used, 0.1% at 100 µM, did not modulate VGCC currents in recording solution.  
 Depolarization-activated calcium currents (ICa) were evoked from a holding 
potential of −80 mV, with a 135 ms (50 ms for T-type) voltage step to a test potential 
(determined from peak of I-V curve) applied every 10 s. When evaluating ICa 
amplitude in the presence and absence of various compounds, test depolarizations of 
varying durations were applied at a frequency of 0.03–2 Hz, from a holding potential 
of −60, −80 or −100 mV to a test potential determined from an I-V relationship to 
elicit peak inward current. To examine the effects of pulse duration on MONIRO-1 
block and recovery from block, pulses of either 45 or 135 ms for Cav2.2 (30 µM) or 15 
or 50 ms for Cav3.1 (3 µM) were elicited at a frequency of 0.1 Hz (Vh = −80 mV).  
Similarly, to study the frequency dependence of MONIRO-1 inhibition, test pulses (45 
ms for Cav2.2 or 15 ms for Cav3.1) were elicited at rates of 0.03, 0.1 and 0.2 Hz for 
Cav2.2 (10 µM MONIRO-1) and 0.03, 0.1, 0.2, 1 and 2 Hz for Cav3.1 (3 µM 
MONIRO-1). To determine the time constants for activation and inactivation of 
macroscopic currents, we used a single exponential equation to fit the traces in control 
and after MONIRO-1 application. 
 Activation curves were measured from test pulses from -80 to +80 mV every 5 
mV for Cav2.2 and Cav3.1 channels (Vh = −80 mV) before and after MONIRO-1 
application. Steady-state inactivation (SSI) curves were generated from various pre-
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pulse potentials (−120 to 0 mV for Cav2.2; −85 to −20 mV for Cav3.1) of 10 s (Cav2.2) 
or 1 s (Cav3.1). Recovery from inactivation was examined using a double-pulse 
protocol, varying the time between a fully inactivating prepulse and the test pulse 
repeated every 15 s, using a concentration of MONIRO-1 which inhibits ~50% of the 
current. Recovery data was best fit by a double exponential. Currents were filtered at 3 
kHz and sampled at 10 kHz. Leak and capacitive currents were subtracted using a 
−P/4 pulse protocol. Data were stored digitally on a computer for further analysis.  
 
1.3 Data analysis. 
 Data analysis and graphs were built using OriginPro (Origin Lab Corporation, 
North Hampton, MA, USA).  Concentration-response curves were generated by 
plotting current in the presence of MONIRO-1 (Icompound) over current prior to 
application (Icontrol) versus a range of MONIRO-1 concentrations tested.  Typically, 4-6 
concentrations per channel were screened with 5-9 cells per concentration.  
Concentration-response data was plotted using a rectangular hyperbola assuming a 
Hill coefficient of 1, using the following expression,  
(Icompound/Icontrol) = 1/(1+IC50/[drug]),  
where IC50 is the concentration at which half-maximal inhibition was observed. 
 Steady-state activation and inactivation curves were generated using a modified 
Boltzmann equation,  
G = 1/(1+exp((Vm-V0.5)/κa)),  
where Vm is the test potential, V0.5 is the half-maximal activation potential and κa is 
the slope factor.  SSA and SSI data were each recorded from 5-7 individual 
experiments per channel examined.  Recovery from inactivation curves were the 
results from 5-6 independent experiments where the complete set of recovery from 
inactivation time points were acquired.  The data was fit using a double exponential of 
the following equation,  
I = 1+Afast *exp(-t/τfast) + Aslow *exp(-t/τslow),  
where τ is the fast and slow time constant, t is the recovery time and A is the 
amplitude of the fast and slow time constants.  Statistical significance of P < 0.05 was 
determined using unpaired Student’s t-tests or one-way ANOVA using Tukey post hoc 
test.  All data reported as mean ± standard error. 
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2.  RESULTS 
3.1 Selective inhibition of human N- and T-type calcium channel subtypes. 
 Whole-cell calcium currents were elicited by depolarizing pulses at a frequency of 
0.1 Hz from a holding potential of −80 mV. MONIRO-1 reversibly inhibited channel 
currents mediated by Cav3.2 (IC50 1.7 ± 0.1 µM, n = 5-9 cells/concentration), Cav3.1 
(IC50 3.3 ± 0.3 µM, n = 5-6 cells/concentration), Cav3.3 (IC50 7.2 ± 0.3 µM, n = 5 
cells/concentration) and Cav2.2 (IC50 34.0 ± 3.6 µM, n = 5-7 cells/concentration) (Fig. 
2 and 3A). The effects of MONIRO-1 were further investigated on a panel of VGCCs. 
At 100 µM, MONIRO-1 had no apparent effect on Cav2.1 (n = 5) or Cav2.3 (n = 5) 
(Fig. 3B), but inhibited Cav1.2 and Cav1.3-mediated currents by 45.8 ± 0.9% (n = 5) 
and 27.0 ± 1.2% (n = 5), respectively. 
 In comparison, Z160/NP118809 (Zamponi et al., 2009) inhibited Cav2.2-mediated 
currents with an IC50 of 0.28 ± 0.02 µM (n = 5-6 cells/concentration), without affecting 
Cav3.1 currents (maximal concentration tested 1 µM, Table 1). Application of 10 µM NNC 
55-0396, a T-type calcium channel inhibitor, inhibited hCav3.2 currents by 96 ± 3% (n = 5).  
Furthermore, Z160/NP118809 inhibited hERG channels with an IC50 of 7.4 µM (Zamponi et 
al., 2009) whereas 100 µM MONIRO-1 did not inhibit hERG channel-mediated K+ currents 
(Table 1). Table 1 compares the IC50 values obtained for MONIRO-1 inhibition of L-, P/Q-, 
N-, R- and T-type calcium channels and the hERG potassium channel, with that of the control 
compounds, Z160/NP118809 and NNC 55-0396, and other known N- and T-type calcium 
channel inhibitors where electrophysiology data was obtained across a large portion of the 
voltage-gated calcium channel subtypes.  
 The current inhibition properties varied between the different MONIRO-1-
sensitive Cav subtypes, so we analysed the interaction between MONIRO-1 and T-type 
(Cav3.1) and N-type (Cav2.2) calcium channels.  
 
3.2 Differential modulation of N- and T-type calcium channels: dependence on 
frequency and holding potential. 
 We examined the inhibitory characteristics of MONIRO-1 at different test pulse 
durations and frequencies on Cav2.2 (Fig. 4A-B) and Cav3.1 (Fig. 5A-B), as 
representatives of the VGCC types targeted by MONIRO-1. Cav2.2 currents in 
response to shorter (45 ms) depolarizations were 1.5-times more sensitive to 
MONIRO-1 inhibition than those elicited by a longer (135 ms) pulse. Channels held 
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open by the longer pulse also recovered more completely from block (82 ± 9%, n = 5) 
than those briefly opened (45 ms; 47 ± 3%, n = 5) (Fig. 4A). In agreement with these 
findings, higher frequency stimulation of Cav2.2 channels rendered a population of 
channels that was more potently inhibited by MONIRO-1 (0.03, 0.1 and 0.2 Hz; Fig. 
4B). At a frequency of 0.2 Hz, MONIRO-1 inhibited Cav2.2 current by 29 ± 1% (n = 
5), whereas at 0.1 and 0.03 Hz, only 21 ± 1% (n = 5) and 16 ± 1% (n = 5) of the 
current amplitude was inhibited, respectively. Interestingly, the effects of MONIRO-1 
on Cav2.2 channels are in marked contrast to its effects on Cav3.1 channels (Fig. 5A-
B). In the case of Cav3.1, pulse duration did not affect Cav3.1-mediated current 
inhibition (% block 15 ms: 43 ± 3%, n = 5; and 50 ms: 51 ± 7%, n = 5), recovery from 
inhibition (% recovery 15 ms: 95 ± 1.3%, n = 5; and 50 ms: 99 ± 0.8%, n = 5) or 
frequency dependence of block over the same range as those tested for Cav2.2 (% 
block at 0.2 Hz = 43 ± 1.5%, n = 5; 0.1 Hz = 42 ± 2.3%, n = 5; and 0.03 Hz = 44 ± 
1.6%, n = 5). However, at faster rates of 1 and 2 Hz, there was a significant increase in 
MONIRO-1 block of Cav3.1 (% block at 1 Hz = 61.0 ± 1.5%, n = 6; and 2 Hz = 71.0 ± 
2.0%, n = 5).  This would increase 3-fold the affinity for channels firing at faster 
frequencies of 2 Hz compared to those firing at rates <0.2 Hz. 
 To further explore the differential effects of MONIRO-1 on Cav2.2 and Cav3.1 
channels, we investigated the effect of membrane holding potential on block of Cav2.2 
and Cav3.1.  MONIRO-1 could more effectively block Cav2.2 channels at more 
depolarized potentials (block at −100 mV = 34 ± 1.8%; −80 mV = 43 ± 3.2%; and −60 
mV = 77 ± 5.5%, n = 5). In contrast, block at all of the holding potentials tested did 
not affect the degree by which MONIRO-1 inhibited Cav3.1 channels (block at −100 
mV = 41 ± 0.5%; −80 mV = 46 ± 5.1%; and −60 mV = 43 ± 0.6%, n = 5) (Fig. 4C and 
5C). This result highlights the state-dependent differences between MONIRO-1 
inhibition of Cav2.2 and Cav3.1 channels. 
 
3.3 Effects of MONIRO-1 on N- and T-type calcium channel activation, 
inactivation and recovery from inactivation. 
 To identify any effects MONIRO-1 may have on calcium current kinetics and 
understand the mechanisms behind the enhanced inhibition at depolarised membrane 
potentials, we examined its effects at half-maximal concentrations on Cav2.2 and 
Cav3.1 activation and SSI (Fig. 4D and 5D). Exposure to MONIRO-1 did not affect 
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the voltage-dependence of activation of Cav2.2 (control V0.5 = 12.5 ± 0.5 mV, n = 5; 
MONIRO-1 V0.5 = 12.4 ± 0.4 mV, n = 5, respectively) or Cav3.1 (control V0.5 act = 
−34.0 ± 0.4 mV, n = 7; MONIRO-1 V0.5act = −34.4 ± 0.6 mV, n = 7) (Table 2). 
However, there was a significant ~10 mV hyperpolarizing shift in Cav2.2 SSI (control 
V0.5 inact = −41.3 ± 0.7 mV, n = 5; MONIRO-1 V0.5 inact = −52.9 ± 1.3 mV, n = 5; P < 
0.05). An apparent decrease in the voltage-dependence of SSI was also seen (control 
slope factor, 5.3 ± 0.6, n = 5; MONIRO-1 slope factor, 10.2 ± 1.2, n = 5; P < 0.05). 
However, no significant changes were observed in Cav3.1 SSI in the presence of 
MONIRO-1 (control V0.5 inact = −53.5 ± 0.6 mV, n = 6; MONIRO-1 V0.5 inact = −55.1 ± 
0.6 mV, n = 6) or voltage-dependence of SSI (control slope factor, 4.4 ± 0.6, n = 6; 
MONIRO-1 slope factor, 6.1 ± 0.5, n = 6).  Channel activation and inactivation time 
constants were examined in the absence and presence of MONIRO-1 on Cav2.2 (30 
µM) and Cav3.1 (3 µM).  MONIRO-1 has no effect on either the activation or 
inactivation time constants of Cav2.2 (Table 2).  However, MONIRO-1 application 
increased both activation (control: 1.90 ± 0.08 ms, n = 5; MONIRO-1: 3.45 ± 0.51 ms, 
n = 5: P <0.05) and inactivation time constants (control: 10.78 ± 0.52 ms, n = 5; 
MONIRO-1: 17.91 ± 0.74 ms, n = 5, P < 0.5) (Table 2). 
 Finally, we investigated the effect of MONIRO-1 on Cav2.2 and Cav3.1 channel 
recovery from inactivation. MONIRO-1 had no observed effect on Cav2.2 recovery 
from inactivation time constants or their relative contribution to either time constants 
(control τfast = 0.22 ± 0.1 s, Afast = 57 ± 8.5%; τslow = 2.8 ± 0.7 s, Aslow = 45 ± 8.6%; 
MONIRO-1 τfast = 0.14 ± 0.1 s, Afast = 43 ± 7.0%; τslow = 2.4 ± 0.4 s, Aslow = 58 ± 6.2%, 
n = 5 respectively). However, MONIRO-1 slowed Cav3.1 recovery from inactivation 
by decreasing the relative contribution of the fast recovery time constant while 
increasing the contribution of the slow time constant (control τfast = 0.051 ± 0.008s, 
Afast = 80.1 ± 5.1%; τslow = 0.20 ± 0.11 s, Aslow = 21.8 ± 5.4%; MONIRO-1 τfast = 0.026 
± 0.007s, Afast = 29.6 ± 4.2%; τslow = 0.33 ± 0.03s, Aslow = 70 ± 4.1%, n = 6; P < 0.05). 
Therefore, MONIRO-1 can inhibit Cav3.1 more efficiently at firing frequencies > 1 Hz 
(Fig. 5B), as indicated by the slowed recovery from inactivation and frequency 
dependence, such as those prevailing in hyperexcitable neurons (Cain et al., 2010). 
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3.  DISCUSSION 
 
 In this study, we examined the effects of an ortho-phenoxyanilide on the inhibition 
and biophysical properties of VGCCs. This ortho-phenoxyanilide, MONIRO-1, is a 
low molecular weight compound and was selected for its ability to inhibit VGCCs in a 
high-throughput calcium influx assay (Gleeson et al., 2015).  To ascertain its 
selectivity and mode of action, we examined its potency of block and biophysical 
properties on a variety of VGCCs. MONIRO-1 was shown to be a N- and T-type 
calcium channel inhibitor with advantageous biophysical properties, including state- 
and use-dependence. It specifically targets Cav3.2 and Cav2.2, which have been 
implicated in various pain pathways, and Cav3.1, which is involved in cell signalling 
and epilepsy (Choi, 2013; Waxman et al., 2014). 
 Given that MONIRO-1 inhibits depolarization-activated calcium responses from 
SH-SY5Y cells (Gleeson et al., 2015), we determined its efficacy and selectivity 
against several VGCCs expressed in HEK293 cells. After screening representative 
members of each voltage-gated calcium channel family (L-, N-, P/Q-, R- and T-types), 
we established that MONIRO-1 preferentially inhibits T-type channels (Cav3.1, Cav3.2 
and Cav3.3 channels), modestly interacts with N-type Cav2.2 channels (with 5−20 
times less affinity compared to T-type calcium channels), and has poor efficacy for L-
type (Cav1.2 and Cav1.3 channels IC50 > 100 µM). No other VGCCs investigated 
(P/Q-type Cav2.1; R-type Cav2.3) responded to high concentrations of MONIRO-1. 
hERG, a typical off-target channel of small molecules was not modulated by 
MONIRO-1 at concentrations up to 100 µM.  Subsequently, we characterized the 
mechanism of MONIRO-1 inhibition on its primary targets, N- and T-type calcium 
channels. 
 In the present study, MONIRO-1 inhibited Cav3.1 with an IC50 of 3 µM, so we 
examined the mechanistic details of this inhibition. Many T-type calcium channel 
inhibitors have been identified in assays looking for inactivation state-dependent 
inhibitors.  These studies have led to compounds that predominantly bind and alter 
steady-state inactivation, including TTA-A2, A-1048400 and NNC 55-0396, unlike 
MONIRO-1, which does not affect steady-state inactivation of Cav3.1.  MONIRO-1 (3 
µM) significantly slowed down both channel activation and inactivation kinetics 
without discernible effects of MONIRO-1 on both V0.5act and V0.5inact.  MONIRO-1 
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slowed recovery of Cav3.1 from inactivation at rates >1 Hz which was reflected as an 
increase in current inhibition at 1 and 2 Hz (Figure 5B,E) suggesting that MONIRO-1 
would preferentially target epileptic firing neurons over normal firing neurons. Taken 
together, the lack of effect of MONIRO-1 on other biophysical properties examined, 
including the lack of effect of holding potential, suggests that it acts by binding to 
prevent Cav3.1 channels from transitioning from a non-conducting state to the open 
state. Therefore, the prolonged recovery from inactivation caused by MONIRO-1 
inhibition of Cav3.1-mediated currents is likely due to the slower dissociation of the 
compound from the open-blocked channels, or due to it accelerating channel 
transitions into a slow inactivated channel conformation. A similar phenomenon has 
been observed for mibefradil inhibition of Cav2.1 channels (Timin et al., 2004).  
 Cav3.1 channels are key players in the circuitry involved in sleep including the 
reticular thalamic nucleus, thalamic relay neurons and neocortical pyramidal cells 
(Chen et al., 2014). Cav3.1 channels are highly expressed in thalamocortical neurons 
(Kim et al., 2001; Song et al., 2004), where they initiate entry of these neurons into 
bursting mode − a typical activity mode in absence seizures (Cain et al., 2013). 
Consequently, Cav3.1 has been directly linked to absence epilepsies (Kim et al., 2001). 
Disease mutations in Cav3.2 have also been linked to both rat models and human 
idiopathic generalized epilepsy (Khosravani et al., 2005; Powell et al., 2009)  
suggesting that inhibitors of both Cav3.1 and Cav3.2 could decrease neuronal firing 
induced by hyperactivity of these channels during epilepsy.  Compound Z944, which 
has higher affinity for the inactivated state of T-type calcium channels over the resting 
state, reduced seizure activity in terms of time spent in seizure and the total number of 
seizures per hour (Tringham et al., 2012). During burst firing, VGCCs repetitively 
open and close at frequencies of 5-10 Hz (Cain et al., 2010). Ideally, an anti-
epileptogenic drug targeting Cav3.1 or Cav3.2 channels in epileptogenic foci, that is, 
on neurons in bursting mode where the channels are in the open state. Our results 
suggest that MONIRO-1 modulates Cav3.1 channels by holding the channel in a non-
conducting state thus prolonging recovery from inactivation, which makes the 
compound well suited for the study and/or potentially for the amelioration of Cav3.1 or 
Cav3.2-mediated epileptogenesis in neurons entering bursting mode. 
 Considerable research into pain physiology has focused on voltage-gated N- and 
T-type calcium channels. Cav3.2 channels are expressed in peripheral sensory neurons, 
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where they modulate pain processing by controlling dorsal root ganglion 
neuroexcitability (Carbone et al., 1984). Cav2.2 channels are located at presynaptic 
terminals in the central nervous system, where they modulate neurotransmitter release 
and fast synaptic transmission (Wheeler et al., 1994). MONIRO-1 inhibits Cav2.2 
under resting state conditions with an IC50 of ~30 µM, which is approximately 10-fold 
higher than that observed the T-type channels. However, the effect of MONIRO-1 on 
Cav2.2 is enhanced at higher frequencies, where faster pacing of the channel increased 
inhibition. At frequencies as high as 0.2 Hz (the maximum tested), the apparent 
affinity increased to ~20 µM, with no observable change to the time course of 
activation or inactivation of the channel (Fig. 4B and Table 2).   
 Following this observation, we examined MONIRO-1’s potential state 
dependence. Short (45 ms) depolarizing test pulses produced greater inhibition of 
Cav2.2 as well as less recovery after washout compared to a longer (135 ms) test pulse, 
suggesting a possible decrease in affinity for the open and/or inactivated state (Fig. 
4A).  MONIRO-1 had a pronounced effect on Cav2.2 channel SSI that was not 
paralleled in Cav3.1 (Fig. 4D) as well as strong dependence on holding potential, At 
−60 mV ~80% of the whole-cell current was inhibited compared to −100 mV where 
only ~35% of the current was blocked (Fig. 4C). Such a hyperpolarizing shift in SSI 
and the dependence on holding potential suggests that MONIRO-1 preferentially binds 
to the inactivated state of N-type calcium channels (Bean, 1984; Bean et al., 1983; 
Sanguinetti et al., 1984).  Interestingly, unlike its effect on T-type calcium channels, 
MONIRO-1 did not influence N-type calcium channel recovery from inactivation (Fig. 
5E) suggesting a distinct mode of action against the two channel families.   
 Nociceptive stimuli cause depolarization, calcium channel opening, intracellular 
[Ca
2+
] increase and neuronal hyper-excitability evidenced by faster firing rates 
(Winquist et al., 2005). Nociceptive stimuli reduce the effective open time and 
increase the frequency of channel opening (Winquist et al., 2005).
 
Sustained neuronal 
firing in pain syndromes increases cytosolic calcium levels in the dorsal horn and 
shifts calcium channels into the inactivated state. Therefore, drugs that target Cav2.2 
are best suited to ‘prefer’ those in the inactivated state (predominant in pain 
syndromes), allowing normal neurotransmitter release signalled by these channels in 
neurons not in a pain state.  
 
16 
 
 A few compounds have recently reported to exhibit use- and/or state-dependent 
inhibition of calcium channels involved in pain signalling, including A-1048400 (Scott 
et al., 2012) (compound 3, Fig. 1), Z160/NP118809 1 (Zamponi et al., 2009), and 
TROX-1 (Abbadie et al., 2010). To explore MONIRO-1 inhibitory mechanism of 
Cav2.2, we examined stimulation conditions comparable with those occurring in the 
physiological setting. Given that Cav2.2 channels can potentially accumulate in the 
inactivated state in hyperactive pain state conditions (Winquist et al., 2005), the 
selective effect of MONIRO-1 on channels in this state could be a valuable 
pharmacological property that would enable therapeutic targeting during neuropathic 
pain treatment. Frequency dependence and preference of MONIRO-1 for the 
inactivated Cav2.2, suggest that it or related compounds may prove useful in the 
prevention of high-frequency firing episodes, an important signalling mode occurring 
during pain transmission. Therefore, MONIRO-1 may preferentially inhibit channels 
in hyperexcitable states in pain-specific loci, leaving normally firing neurons 
unaffected (Liao et al., 2011). 
 
4. CONCLUSION 
 
 We identified MONIRO-1 as a low molecular weight voltage-gated calcium 
channel antagonist with 10−100-fold higher affinity for Cav3.1, Cav3.2, Cav3.3 and 
Cav2.2 than other classes of VGCCs examined. MONIRO-1 is a valuable tool for the 
study of VGCCs because it inhibits N- and T-type calcium channels through distinct 
mechanisms. Given its state- and use-dependent inhibition of Cav2.2 (preferentially 
inhibits the inactivated state) and Cav3.1 (prohibiting channel transitions to the open 
state), while exhibiting frequency dependent block of both channels.  MONIRO-1 is a 
novel lead compound that could be used to develop Cav channel blockers to treat 
VGCC pathologies, including neuropathic pain and epilepsy.  MONIRO-1 shows a 
novel mechanism of block of hCav3.1 compared to previously described T-type 
calcium channel blockers, in that it slows channel activation and inactivation kinetics 
and traps channels at high frequency firing (>1 hZ) from transitioning to the open state 
while not altering steady-state inactivation.  Prior to in vivo assessment of their 
analgesic potential, MONIRO-1 and analogues need to be characterised at other 
voltage-gated ion channels in pain pathways, including Nav1.7 and Nav1.8. 
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FIGURE LEGENDS  
 
Figure 1. Chemical structures of compounds 1 (Z160/NP118809), 2 (MONIRO-1) and 3 
(NNC 55-0396) relevant to this study. 
 
Figure 2. MONIRO-1 inhibition of human Cav2.2- and Cav3.1-mediated currents in HEK293 
cells. A. Superimposed whole-cell Ca
2+
 currents recorded from HEK293 cells stably 
expressing human N-type calcium (hCav2.2 ) channels (α1B + β3 + α2δ1) in response to 
depolarizing pulses (135 ms duration) to +20 mV from a holding potential of −80 mV.  
Representative current traces obtained in the absence (a) and presence of 50 (b) and 100 µM 
(d) MONIRO-1, and after respective washouts (c, e). B. Peak inward Ca
2+
 current amplitude 
plotted as a function of time. Time course of inhibition and current amplitude recovery in the 
presence and following washout of 50 and 100 µM MONIRO-1. Representative currents 
shown in (A) were obtained at the times indicated by the lower case letters. C. Superimposed 
whole-cell Ca
2+
 currents recorded from HEK293 cells transiently expressing human T-type 
calcium channel, hCav3.1. These Ca
2+
 currents are in response to depolarizing pulses (50 ms 
duration) to −25 mV from a holding potential of −80 mV. Representative current traces 
obtained in the absence (a) and presence of 10 (b) and 100 µM (c) MONIRO-1. D. Peak 
inward Ca
2+
 current amplitude plotted as a function of time. Time course of inhibition and 
recovery of current amplitude in the absence (a) and presence of 10 (b) and 100 µM (c) 
MONIRO-1. 
 
Figure 3. MONIRO-1 inhibition of voltage-gated calcium channels. A. 
Concentration–response of MONIRO-1 at hCav2.2 (open square), hCav3.1 (open 
upward triangle), hCav3.2 (open circle) and hCav3.3 (open downward triangle) 
channels expressed in HEK293 cells. Fitted curves gave IC50 values of 34 ± 3.6 µM (n 
= 5-7 cells per concentration) towards hCav2.2; 3.3 ± 0.3 µM (n = 5-6 cells per 
concentration) against hCav3.1; 1.7± 0.1 µM against hCav3.2 (n = 5-9 cells per 
concentration); and 7.2 ± 0.3 µM (n = 5 cells per concentration) against hCav3.3. B. 
Fraction of current inhibited by 100 (solid) or 10 µM (striped) MONIRO-1 at Cav1.3, 
Cav2.1, Cav2.2, Cav2.3, Cav3.1 and Cav3.2 channels. Cells were held at −80 mV and 
pulsed at 0.1 Hz to the voltage determined to elicit the peak inward current previously 
determined from an I-V protocol. The number of cells is indicated in parentheses. 
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Figure 4. MONIRO-1 block of human Cav2.2 channels. A. (i) Recovery from block (striped) 
and (ii) fraction blocked (solid) by 30 µM MONIRO-1, with a depolarizing pulse duration of 
45 ms (open bars) or 135 ms (filled bars), from a holding potential of -80mV to a test 
potential that elicits maximal inward current, repeated every 10 s. The number of cells is 
indicated in parentheses. B. Fraction of current inhibited by 10 µM MONIRO-1 at three 
different frequencies (0.03, 0.1, and 0.2 Hz; holding potential −80 mV). The number of cells 
is indicated in parentheses. C. Effect of holding potential (−100, −80 and −60 mV) on the 
fraction of current blocked by 30 µM MONIRO-1 (pulsed at 0.1 Hz). The number of cells is 
indicated in parentheses. D.  Activation and SSI curves in the absence (control; solid 
symbols) and presence of 30 µM MONIRO-1 (open symbols).  Activation curves were 
generated through indicated depolarizing test pulses (135 ms) from a holding potential of −80 
mV, repeated every 10s.  For SSI curves, selected prepulse potentials (−120 to 0 mV in 5 mV 
increments for 10 s) were applied prior to a test pulse (135 ms) determined from the peak 
current, repeated every 15 s from a holding potential of −80 mV.  E. Recovery from 
inactivation in the absence (control; solid symbols) and presence of 30 µM MONIRO-1 (open 
symbols). A two-pulse protocol (Inset) was repeated every 15 s, where the time was varied 
between the first fully inactivating pulse and the test pulse (0-10 s). * P<0.05 and n.s.= not 
statistically significant, based on student’s t-test. 
 
Figure 5. MONIRO-1 block of human Cav3.1 channels. A. (i) Bar graph showing recovery 
from block (striped) and (ii) fraction blocked (solid) by 3 µM MONIRO-1, with a 
depolarizing pulse duration of 15 ms (open bars) or 50 ms (filled bars), from a holding 
potential of −80mV repeated every 10 s. The number of cells is indicated in parentheses. B. 
Bar graph of the fractional current inhibited by 3 µM MONIRO-1 at five different 
frequencies (0.03, 0.1, 0.2, 1 and 2 Hz; holding potential −80 mV). The number of cells is 
indicated in parentheses. C. Effect of holding potential (−100, −80 and −60 mV) on the 
fraction of current inhibited by 3 µM MONIRO-1 (pulsed at 0.1 Hz). The number of cells is 
indicated in parentheses. D.  Activation and SSI curves in the absence (control; solid 
symbols) and presence of 3 µM MONIRO-1 (open symbols). Activation curves were 
generated through indicated depolarizing test pulses (50 ms) from a holding potential of −80 
mV, repeated every 10s.  For SSI curves, selected prepulse potential values (-85 to -20 mV in 
5mV increments for 1 s) were applied prior to a test pulse (50 ms) determined from the peak 
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current, repeated every 10 s from a holding potential of −80 mV.  E.  Recovery from 
inactivation in the absence (control; solid symbols) and presence of 3 µM MONIRO-1 (open 
symbols). A two-pulse protocol (Inset) was repeated every 15 s, where the time was varied 
between the first fully inactivating pulse and the test pulse.  * P<0.05 and n.s.= not 
statistically significant based on student’s t-test. 
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Table 1.  Comparison of IC50 values obtained for MONIRO-1 inhibition of L-, P/Q-, N-, R- and T-type calcium channels and the hERG 
potassium channel, with control compounds Z160/NP118809 and NNC 55-0396, and other known N- and T-type calcium channel inhibitors.  
 L-type P/Q-type N-type R-type T-type hERG 
 Z160/NP118809 
(Zamponi et al., 2009)  
12 µM
†
 (Cav1.2) − 0.28 µM
*
 − − 7.4 µM 
* 
MONIRO-1  
27% @ 100 µM (Cav1.3) 
46% @ 100 µM 
(Cav1.2) 
>100 µM 34 µM >100 µM 
3.3 µM (Cav3.1) 
1.7 µM (Cav3.2) 
7.2 µM (Cav3.3) 
>100 µM 
 A-1048400  
(Scott et al., 2012) 
28 µM  1.3 µM 0.8 µM − 0.9 µM (Cav3.2) − 
Z944  
(Tringham et al., 2012)  
32 µM (Cav1.2) − 11 µM − 
0.05 µM (Cav3.1) 
0.16 µM (Cav3.2 ) 
7.8 µM 
NNC 55-0396  
(Chen et al., 2014) 
− − − − 
6.8 µM
†
 (Cav3.1) 
96% @10 µM* (Cav3.2) 
− 
Ziconotide  
(Wang et al., 2016)  
− >10 µM 0.18 µM
†
 − − − 
TTA-A2  
(Kraus et al., 2010)  
>30 µM
†
 (Cav1.2) >30 µM
†
 >30 µM
†
 >30 µM
†
 
0.09 µM (Cav3.1) 
0.09 µM (Cav3.2) 
− 
TROX-1  
(Swensen et al., 2012)  
− 0.29 µM 0.19 µM 0.28 µM − − 
*
This work. 
†
Studies were performed with HEK293 cells stably expressing the desired voltage-gated calcium channel. −, not tested. 
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Table 2.  Comparison of activation and inactivation parameters between Cav2.2 and Cav3.1 before and after application of MONIRO-1 
 
Cav2.2 Cav3.1 
 
Control  MONIRO-1 (30 µM)
+
 Control MONIRO-1 (3 µM)
+
 
tau activation 1.81 ± 0.15 ms (5) 1.51 ± 0.17 ms (5) 1.90 ± 0.08 ms (5) 3.45 ± 0.51 ms (5)* 
tau inactivation 61.75 ± 13.69 ms (5) 44.45 ± 7.61 ms (5) 10.78 ± 0.52 ms (5) 17.91 ± 0.74 ms (5)* 
V0.5 activation 12.5 ± 0.5 mV (5) 12.4 ± 0.4 mV (5) −34.0 ± 0.4 mV (7) −34.4 ± 0.6 mV (7) 
V0.5 inactivation −41.3 ± 0.7 mV (5) −52.9 ± 1.3 mV (5)* −53.5 ± 0.6 mV (6) −55.1 ± 0.6 mV (6) 
Slope factor 5.3 ± 0.6 (5) 10.2 ± 1.2 (5)* 4.4 ± 0.6 (6) 6.1 ± 0.5 (6) 
 
*P <0.05 compared to control, students t-test. 
+
concentration chosen based on IC50 of individual channel 
 
 
 





